Fatty Liver Disease

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated August 1, 2026

Overview

Promoting liver health through early insight and action.

Indian MASLD Genetics - APOC3 May Influence Susceptibility, While PNPLA3 Tracks Fibrosis Progression: JCEH | August 2026

Introduction: MASLD affects a large proportion of Indian adults, but genetic drivers may differ by ancestry and may influence different stages of disease. This North Indian candidate-gene study examined whether specific variants are associated with...

AGILE 3+ and AGILE 4 Accurately Identify Advanced Fibrosis and Cirrhosis in Indian MASLD: JCEH | August 2026

Introduction: Accurate fibrosis assessment is central to risk stratification in MASLD, but commonly used non-invasive tests (NITs) often leave many patients in an indeterminate “grey zone.” This multicenter ICON-D study validated AGILE 3+ and AGILE...

Statins in MASLD: Frontiers in Pharmacology | July 2026

Introduction: Statins are routinely prescribed in metabolic dysfunction-associated steatotic liver disease (MASLD) to reduce cardiovascular risk, but emerging evidence suggests their benefits may extend directly to the liver. This translational review explores how statins may...

Steatotic Liver Disease Is a Dynamic Spectrum: Nature Reviews Gastroenterology & Hepatology | August 2026

Introduction: Steatotic liver disease (SLD) is increasingly recognized not as a collection of separate disorders but as a dynamic spectrum driven by interacting metabolic and alcohol-related factors. Obesity, diabetes, hypertension, dyslipidaemia, and alcohol frequently coexist,...

Zalfermin Plus Semaglutide Fails to Add Fibrosis Benefit in MASH: The Lancet | September 2026

Introduction: Patients with MASH and advanced fibrosis remain at substantial risk of cirrhosis and liver-related complications. Because MASH involves multiple metabolic and fibrogenic pathways, combination therapy is attractive. This Phase II trial evaluated whether the...

Tofogliflozin Modulates Gut Microbial Amino Acid Metabolism in MASLD: JOG | August 2026

Introduction: The gut–liver axis plays a central role in the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). While previous studies have focused on changes in gut bacterial composition, emerging evidence suggests that...

Cytochrome P450 Reductase in MASLD: Nature Reviews Gastroenterology & Hepatology | August 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) involves complex disturbances in hepatic lipid metabolism, oxidative stress, inflammation, and mitochondrial function. NADPH:cytochrome P450 oxidoreductase (CPR), encoded by POR, is the essential electron donor for microsomal cytochrome...

Gut–Brain Signalling in Eating and Obesity: Nature Reviews Gastroenterology & Hepatology | August 2026

Introduction: Eating behaviour is governed by complex interactions between the gastrointestinal tract and the brain that generate hunger, satiation, and satiety. This review examines how gut-derived mechanical and nutrient signals are transmitted and integrated within...

AI-Powered Blood Test Detects Liver Cancer Across Diverse Populations: Cell | July 2026

Researchers at Johns Hopkins have validated an AI-powered DELFI liquid biopsy that accurately detected hepatocellular carcinoma (HCC) in geographically and biologically distinct high-risk populations. Key findings: ✅ Successfully detected HCC in patients from Romania (viral...

LITMUS Imaging Study for MASH and Fibrosis: Nature Medicine | July 2026

Introduction: Reliable noninvasive biomarkers are essential to replace liver biopsy for diagnosing metabolic dysfunction-associated steatohepatitis (MASH) and staging fibrosis. The prospective multicenter LITMUS Imaging Study evaluated the diagnostic performance of leading imaging, serum, and composite...

Fibrosis Remains the Strongest Predictor of Outcomes in Global-MASLD Study: Hepatology | July 2026

Introduction: Fibrosis is the principal determinant of long-term outcomes in metabolic dysfunction–associated steatotic liver disease (MASLD). This large international Global-MASLD study evaluated clinical predictors of advanced fibrosis and assessed the prognostic value of noninvasive fibrosis...

Beyond BMI: Contemporary Guidelines for Obesity Care: Nature Reviews Endocrinology | July 2026

Introduction: Obesity is increasingly recognized as a chronic, adiposity-based disease rather than a condition defined solely by body mass index (BMI). Recent guidelines from major international organizations have introduced new diagnostic frameworks that incorporate body...

Global Performance of Noninvasive Fibrosis Tests in MASLD: Hepatology | July 2026

Introduction: Noninvasive tests (NITs) have become central to the diagnosis and staging of metabolic dysfunction–associated steatotic liver disease (MASLD), reducing reliance on liver biopsy. However, most validation studies have been performed in selected populations, and...

FMO Score for Identifying At-Risk MASH in Obesity: Hepatology | July 2026

Introduction: Identifying patients with at-risk metabolic dysfunction–associated steatohepatitis (MASH) is essential because they carry a substantially higher risk of cirrhosis, hepatocellular carcinoma, and liver-related mortality. Although liver biopsy remains the diagnostic standard, it is impractical...

Reclassifying Paediatric NAFLD Under the SLD Framework: Hepatology | July 2026

Introduction: The transition from non alcoholic fatty liver disease (NAFLD) to the steatotic liver disease (SLD) nomenclature has redefined metabolic dysfunction–associated steatotic liver disease (MASLD) as the principal subtype. While studies in adults have shown...

Transient Elastography Matches Biopsy for Predicting Liver Outcomes in MASLD: Hepatology | July 2026

Introduction: Accurate prediction of liver-related events (LREs) is essential for risk stratification and therapeutic decision-making in metabolic dysfunction–associated steatotic liver disease (MASLD). Although liver biopsy remains the reference standard for fibrosis assessment, vibration-controlled transient elastography...

A Novel Metabolic Target (CD59) for Obesity, Insulin Resistance, and Fatty Liver npj Metabolic Health and Disease | June 2026

Introduction: Obesity, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD) are closely linked metabolic disorders with limited disease-modifying therapies. This study identifies CD59, traditionally known as a complement regulatory protein, as a previously unrecognized...

Comparative Effectiveness of Anti-Obesity Drugs: BMJ | July 2026

Introduction: The treatment of obesity has entered a new era with several highly effective pharmacological agents. This large systematic review and network meta-analysis compared the efficacy, safety, cardiovascular outcomes, and quality of life associated with...

First Clinical Guidelines for Cardiovascular–Kidney–Metabolic (CKM) Syndrome: JAMA | July 2026

Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the interconnected relationship between obesity, type 2 diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD). These first multidisciplinary guidelines from the AHA, ACC, ADA, and American Society of Nephrology...

MASLD, Obesity & T2D: Shared Disease Pathways: Frontline Gastroenterology | July 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD), obesity, and type 2 diabetes (T2D) represent interconnected global epidemics that frequently coexist and amplify one another. Together, they accelerate liver disease progression, increase cardiometabolic complications, and substantially...

Type 2 Diabetes Accelerates Liver Fibrosis in Chronic Hepatitis B with Fatty Liver: Hepatology | May 2026

Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...

A Novel Gut-Targeted Therapy for MASH (DT-109): Journal of Clinical Investigation | July 2026

Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...

DT-109- A Novel Gut-Targeted Therapy for MASH: JCI | July 2026

Tirzepatide vs SGLT2i in MASLD: Hepatology International | July 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...

Early Weight Regain After GLP-1 RA Discontinuation: Diabetes, Obesity and Metabolism | July 2026

Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...

Incretin-Based Therapy for MASH: Metabolic Target Organ Damage | July 2026

Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...

Metabolic Drivers of MASLD and MASH: Diabetologia | June 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are now recognized as systemic metabolic diseases rather than isolated liver disorders. This review integrates current knowledge on how hormonal, metabolic, inflammatory, and...

AREL1: A New Stellate-Cell Target in MASH Fibrosis: Nature Communications | June 2026

Integrated single-cell and single-nucleus RNA sequencing identified a distinct hepatic stellate cell population associated with MASH-related fibrosis. AREL1 emerged as a characteristic gene of this fibrogenic stellate-cell population and was selectively increased in MASH fibrosis....

Ultra-Processed Foods, MASLD and Cognitive Ageing: Nutrients | June 2026

This review proposes a processing-centred gut–liver–brain axis, positioning MASLD as a metabolic amplifier between ultra-processed food exposure and cognitive decline. Ultra-processed foods are not simply high in sugar, fat, or salt; industrial processing disrupts the...

Updated Care Pathway for MASLD Risk Stratification : Gastroenterology | Jul 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) has emerged as one of the most prevalent chronic liver diseases worldwide, affecting nearly one-third of adults and a majority of individuals with type 2 diabetes. Beyond liver-related...

PPARα Emerges as a Target in Lean MASLD : Acta Pharm Sin B | Jun 2026

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is traditionally linked to obesity, but an increasing number of patients develop significant hepatic steatosis despite having a normal body mass index. This entity, known as lean MASLD,...

Who Should Receive Resmetirom?: CGH | April 2026

Resmetirom is the first FDA-approved therapy for patients with MASH/MASLD and stage F2–F3 fibrosis, creating an urgent need for reliable noninvasive methods to identify treatment candidates. This study evaluated whether currently proposed noninvasive treatment eligibility...

GLP-1RAs Linked to Lower Obesity-Related Cancer Risk : Ann Oncol | June 2026

Introduction: Obesity is a major risk factor for several malignancies, including colorectal, pancreatic, liver, endometrial, and other obesity-associated cancers (OACs). With the growing global burden of obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have rapidly emerged...

AI Fibrosis Mapping Redefines Risk in MetALD and ALD : Gastroenterology | June 2026

Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol-Associated Liver Disease, and the recently recognized MetALD phenotype represent a rapidly expanding spectrum of chronic liver disease with overlapping metabolic and alcohol-related injury. Although steatotic liver disease (SLD)...

Breathomics Redefines Functional Liver Assessment : Clin Liver Dis | May 2026

Introduction Chronic Liver Disease continues to rise globally, driven predominantly by Metabolic Dysfunction-Associated Steatotic Liver Disease and alcohol-associated liver disease. Accurate evaluation of fibrosis severity and hepatic functional reserve remains fundamental for prognostication, transplant assessment...

Histidine–ImP Axis Links Gut, Liver and Vascular Injury in MASLD : Biomed Pharmacother | May 2026

Introduction Metabolic Dysfunction-Associated Steatotic Liver Disease is increasingly recognized as a systemic disorder extending beyond hepatic steatosis and fibrosis. Cardiovascular disease remains the leading cause of mortality in MASLD, yet cardiovascular risk varies markedly among...

Diet Quality Shapes MASLD Fibrosis Progression : Hepatol Commun | May 2026

Introduction Metabolic Dysfunction-Associated Steatotic Liver Disease is increasingly recognized as a major driver of progressive liver fibrosis, cirrhosis and liver-related mortality worldwide. Although obesity, insulin resistance and diabetes are well-established contributors, growing evidence suggests that...

Updated EASO Framework for Obesity Pharmacotherapy : Nat Med | May 2026

Introduction Obesity is increasingly recognized as a chronic, relapsing, multisystem disease requiring long-term, complication-oriented management rather than a purely weight-centric approach. The rapid expansion of anti-obesity pharmacotherapy, particularly incretin-based therapies and emerging combination agents, has...

Global Consensus for MASLD Risk Stratification and Therapy : Clin Gastroenterol Hepatol | May 2026

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) have emerged as dominant causes of chronic liver disease worldwide, paralleling the epidemics of obesity and type 2 diabetes. Fibrosis stage remains the...

Wine, Food and Gut Health Multiomics : Adv Nutr | May 2026

Introduction Wine has historically been investigated for its cardioprotective effects, particularly in the context of the “French paradox,” but emerging evidence suggests that moderate wine consumption may exert broader physiological effects, especially on gut health...

MASLD in Older Adults Demands an Age-Specific Clinical Approach: Frontline Gastroenterology

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is now one of the most common chronic liver diseases worldwide, affecting nearly one in four adults. Although much of the clinical focus has centered on middle-aged populations,...

Nutrition in MASLD: Frontline Gastroenterology | April 2026

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease worldwide and closely parallels the epidemics of obesity and type 2 diabetes. Lifestyle modification remains the first-line, evidence-based treatment,...

AI-Based Hepatic Fibre Phenotyping in MASLD: Hepatology | April 2026

Introduction Metabolically–dysfunction–associated steatotic liver disease (MASLD) is a complex and heterogeneous condition where fibrosis plays a central role in disease progression and hepatocellular carcinoma (HCC) risk. Traditional histological fibrosis staging, although widely used, often fails...

Lean MASLD: Gut | April 2026

Introduction Metabolic dysfunction–associated steatotic liver disease (MASLD) has traditionally been linked with obesity and metabolic syndrome. However, an emerging subset—lean MASLD—is increasingly recognised, particularly in Asian populations. Despite having a normal body mass index, these...

Combination Therapies for MASH: JOH, April 2026

Introduction Metabolically–dysfunction–associated steatohepatitis (MASH) is a complex, multisystem disease driven by obesity, insulin resistance, lipotoxicity, inflammation, and fibrosis. Traditional single-drug therapies have shown limited success because they target only one pathway in a highly heterogeneous...

MASLD in Children and Adolescents: Journal of Hepatology | March 2026

Introduction Pediatric metabolic dysfunction-associated steatotic liver disease is increasingly recognized as one of the most important chronic liver diseases in children and adolescents, paralleling the global rise in obesity and metabolic dysfunction. This review highlights...

Ketogenic Diets in MASLD: Journal of Hepatology | March 2026

Introduction Ketogenic diets, characterized by very low carbohydrate intake and increased fat consumption, have gained significant attention as a potential therapeutic strategy in metabolic dysfunction-associated steatotic liver disease. The rationale is biologically appealing: by reducing...

GLP-1 RA in Gastroenterology: Digestive and Liver Disease | March 2026

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now widely used for type 2 diabetes and obesity, two conditions frequently encountered in gastroenterology practice. Their effects extend far beyond glycemic control and weight loss, influencing the...

Resmetirom and MASLD Spectrum: Hepatology Communi — March 2026

Introduction Metabolically associated steatotic liver disease (MASLD) has become one of the most common causes of chronic liver disease worldwide, closely linked to the global epidemics of obesity and type 2 diabetes. The progressive form,...

Conventional Cardiovascular Risk Scores Underperform in Patients With MASLD: AMJ, March 2026

Metabolically–dysfunction–associated steatotic liver disease (MASLD) is strongly linked to cardiometabolic disorders, and cardiovascular disease (CVD) remains the leading cause of mortality in these patients. However, it is unclear whether commonly used cardiovascular risk prediction tools...

Lean MASLD: Why Exercise Matters More Than Weight Loss: Gastroenterology | March 2026

Introduction – MASLD in Normal-Weight Individuals Metabolically dysregulated steatotic liver disease (MASLD) is commonly linked with obesity and metabolic syndrome. However, a significant subset of patients develop MASLD despite having a normal body mass index...

Dapagliflozin Reduces Liver Fat Independent of Weight Loss in T2D Obesity | Feb 2026 | DOI: 10.1002/oby.70134

Introduction In type 2 diabetes, hepatic steatosis is common and contributes to cardiometabolic risk. SGLT2 inhibitors improve weight and glycemia, but whether they reduce liver fat through weight loss alone or via a direct hepatic...

Do Patients Want MASLD Screening? Hepatology | February 2026

Screening for metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly discussed, but concerns about anxiety, stigma, and overdiagnosis persist. This population-based study from Olmsted County evaluated how individuals perceive the benefits and harms of proactive...

Do ACE Inhibitors and ARBs Improve Liver Outcomes in MASLD?- Hepatology Feb.26

Metabolic dysfunction–associated steatotic liver disease (MASLD) is tightly linked to cardiometabolic comorbidities, particularly hypertension. While blood pressure control is essential for cardiovascular risk reduction, whether antihypertensive drug choice influences liver-related outcomes has remained uncertain. This...

Hypertension Accelerates Liver Disease Progression in MASLD- AJG Feb.26

Introduction Metabolically–dysfunction–associated steatotic liver disease (MASLD) frequently coexists with hypertension, yet blood pressure has traditionally been viewed mainly through a cardiovascular lens. Whether hypertension directly influences liver disease progression and long-term hepatic outcomes has remained...

ANTICIPATE-NASH Beats Biopsy for Event Risk in MASLD- Gastroenterology Feb.26

Introduction In metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis stage on liver biopsy (F3 vs F4) remains the cornerstone for prognosis, surveillance, and clinical trial eligibility. However, real-world experience tells us that not all F3...

Noninvasive markers and Prediction of treatment with Semaglutide (AP&T) - Jan,2026

As of my training cut-off in October 2023, I do not have access to specific information about a publication titled "Noninvasive markers and Prediction of treatment with Semaglutide (AP&T) - Jan, 2026." However, I can...

HCC Risk Prediction in Chronic HBV With Metabolic Dysfunction

Hepatocellular carcinoma (HCC) risk prediction in patients with chronic hepatitis B virus (HBV) infection who also have metabolic dysfunction is a complex but crucial aspect of clinical care. This population faces a compounded risk due...

Phase III Trial of Norursodeoxycholic Acid in MASLD

The Phase III trial of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) was designed to evaluate the efficacy and safety of this promising therapeutic option in a broader patient population. MASLD is a...

FIB-4 as a Referral Index for Coronary Artery Calcification in MASLD

The Fibrosis-4 (FIB-4) index has emerged as a potentially valuable tool for assessing the risk of coronary artery calcification (CAC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). This study highlights the utility of...

Semaglutide for MASLD: AASLD Practice Guidance November 2025

As of my knowledge cutoff in October 2023, I cannot provide specific details about the AASLD Practice Guidance from November 2025 regarding semaglutide for MASLD (metabolic dysfunction-associated steatotic liver disease). However, based on the provided...

M-ACCEL trial

The M-ACCEL trial is a phase IIa study that evaluated the investigational oral drug HU6 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to assess the drug's efficacy in reducing liver fat...

The ELMWOOD- Phase II trial

The ELMWOOD Phase II trial is a clinical study evaluating the efficacy and safety of elafibranor (brand name Iqirvo) for the treatment of primary sclerosing cholangitis (PSC). PSC is a rare, chronic liver disease that...

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist

GLP-1 Receptor Agonist Overview A GLP-1 receptor agonist is a type of medication that mimics the action of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 is a naturally occurring hormone that helps regulate blood sugar levels,...

Tobacco and MASLD

Tobacco use, both active and passive, significantly influences the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Active smoking increases MASLD risk through mechanisms such as oxidative stress, inflammation, and metabolic disruption. Tobacco-induced...

GLP-1 Receptor Agonists and Gastrointestinal Adverse Events

GLP-1 receptor agonists (GLP-1RAs) are medications commonly used to treat type 2 diabetes, obesity, and metabolic liver diseases. A meta-analysis of 55 randomized trials involving over 106,000 participants examined their gastrointestinal safety. The study found...

Autoantibodies and outcome of MASLD

Autoantibodies, specifically ANA (antinuclear antibodies) and ASMA (anti-smooth muscle antibodies), are immune system proteins that mistakenly target the body’s own tissues. These autoantibodies were studied in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) to...

T2DM, GLP-1 Receptor Agonists and Liver Protection

GLP-1 receptor agonists (GLP-1RAs) have emerged as a promising therapeutic option for type 2 diabetes mellitus (T2DM) due to their multifaceted benefits, including significant liver protection. Here is a detailed explanation of their role in...

2D-SWE in MASLD

Two-dimensional shear wave elastography (2D-SWE) is a non-invasive imaging technique used to measure liver stiffness, which helps assess the severity of liver fibrosis. Liver fibrosis occurs when scar tissue builds up in the liver, often...

A new generation of non-invasive tests of liver fibrosis in MASLD

The new generation of non-invasive tests (NITs) for liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) are advanced diagnostic tools developed using machine learning and multitargeting approaches. These tests aim to improve the accuracy...

Targeting Hepatic Stellate cells in MASH

Targeting hepatic stellate cells (HSCs) in metabolic dysfunction-associated steatohepatitis (MASH) represents a promising therapeutic approach to prevent or reverse liver fibrosis, a key driver of disease progression. Below is a detailed explanation of the context,...

Plasma metabolomics prevents MASH related mortality

Plasma metabolomics, a branch of metabolomics focused on analyzing small molecules (metabolites) in blood plasma, plays a promising role in the prevention of metabolic dysfunction-associated steatohepatitis (MASH) and related liver mortality. This approach focuses on...

Exosome-related genes for MASLD-related HCC

Exosome-related genes have gained significant attention for their potential role in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD) to hepatocellular carcinoma (HCC). These genes are involved in the biogenesis,...

Normal ALT, Liver Fibrosis and MASLD

The study you provided investigates the relationship between normal ALT (alanine transaminase) levels, liver fibrosis, and metabolic dysfunction-associated steatotic liver disease (MASLD). Here's a detailed breakdown of the findings and implications for patients with normal...

Rapamycin alleviate intrahepatic inflammation in MASLD

Yes, rapamycin alleviates intrahepatic inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). According to the study, rapamycin's therapeutic effects are primarily mediated through its action on bone marrow-derived macrophages, which are key immune cells involved...

Fisetin against the development of MAFLD

Fisetin, a natural flavonoid found in fruits and vegetables like strawberries and apples, has shown significant potential in combating metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD, a chronic liver condition linked to obesity, insulin resistance,...

Survodutide - Role in MASH

Survodutide is emerging as a promising treatment for metabolic dysfunction–associated steatohepatitis (MASH), a progressive form of metabolic dysfunction–associated steatotic liver disease (MASLD). Survodutide functions as a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors,...

Efruxifermin and MASH

Efruxifermin (EFX) is a promising treatment for metabolic dysfunction-associated steatohepatitis (MASH), a severe progression of metabolic liver disease with limited effective therapies. EFX is a fibroblast growth factor 21 (FGF21) analogue that offers dual benefits...

Rising Global Burden of MASLD

The global burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD, is rising at an alarming rate and poses a significant public health challenge. MASLD is now the most common chronic liver...

Spleen-To-Liver Stiffness Ratio in MASH

The spleen-to-liver stiffness ratio (SSM/LSM) is an emerging noninvasive biomarker that has shown significant potential in characterizing portal hypertension (PH), particularly in patients with metabolic dysfunction-associated steatohepatitis (MASH). Here is a detailed breakdown of the...

GLP-1 and GLP-1/GIP Agonists, Adverse Liver Outcomes and Type 2 DM

GLP-1 receptor agonists (such as semaglutide and liraglutide) and the dual GLP-1/GIP receptor agonist tirzepatide have been studied for their impact on major adverse liver outcomes (MALO) in patients with type 2 diabetes (T2D). These...

Non-invasive score, Advanced fibrosis and MASLD

Non-invasive scores, advanced fibrosis, and metabolic dysfunction-associated steatotic liver disease (MASLD) are interrelated concepts in the context of liver disease diagnosis and management. Here's a detailed explanation of these terms and their relevance based on...

Invasive and noninvasive liver disease assessments and long-term clinical outcomes in MASLD

The study you’ve referenced investigates the utility of invasive and noninvasive liver disease assessments in predicting long-term clinical outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Below is a detailed breakdown of the...

Non invastive criteria for pharmacotherapy in MASLD

Noninvasive criteria for pharmacotherapy in MASLD (Metabolic dysfunction-associated steatotic liver disease) have been a critical focus due to the limitations of existing diagnostic models. Current noninvasive clinical criteria for determining eligibility for resmetirom therapy in...

MASLD Consensus 2025

The MASLD Consensus 2025 represents a unified and standardized approach to the management of Metabolic dysfunction-associated steatotic liver disease (MASLD) and Metabolic dysfunction-associated steatohepatitis (MASH). This consensus was developed using expert opinions and the Delphi...

New Canadian obesity pharmacotherapy guidelines

The new Canadian obesity pharmacotherapy guidelines represent a significant update to the approach for managing obesity in adults. These guidelines, which will remain in effect until May 2025, incorporate the latest evidence and reflect a...

GLP-1 therapy with nutrition and lifestyle guidance

GLP-1 therapy, such as medications like semaglutide and tirzepatide, has emerged as a powerful tool for weight management and metabolic health improvement. However, it is not a standalone solution for long-term success. To achieve optimal...

Mental health, emotional eating, lifestyle factors, and BMI trajectories

The relationship between mental health, emotional eating, lifestyle factors, and BMI (Body Mass Index) trajectories is intricate and multifaceted, as highlighted by the study summarized in the context. Below is a detailed exploration of these...

Canadian guideline on managing obesity in children and adolescents

The Canadian guideline on managing obesity in children and adolescents represents a landmark shift in addressing pediatric obesity as a chronic disease. It is the first dedicated guideline for childhood and adolescent obesity in Canada,...